KR20080103108A - 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법 - Google Patents

신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법 Download PDF

Info

Publication number
KR20080103108A
KR20080103108A KR1020087025237A KR20087025237A KR20080103108A KR 20080103108 A KR20080103108 A KR 20080103108A KR 1020087025237 A KR1020087025237 A KR 1020087025237A KR 20087025237 A KR20087025237 A KR 20087025237A KR 20080103108 A KR20080103108 A KR 20080103108A
Authority
KR
South Korea
Prior art keywords
hcg
days
treatment period
administered
epo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087025237A
Other languages
English (en)
Korean (ko)
Inventor
사무엘 와이스
크리스토퍼 그렉
알렌 다비도프
조셉 터커
Original Assignee
스템 셀 테라퓨틱스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스템 셀 테라퓨틱스 코포레이션 filed Critical 스템 셀 테라퓨틱스 코포레이션
Publication of KR20080103108A publication Critical patent/KR20080103108A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020087025237A 2006-03-17 2007-03-16 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법 Ceased KR20080103108A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US78350006P 2006-03-17 2006-03-17
US60/783,500 2006-03-17
US78913206P 2006-04-05 2006-04-05
US60/789,132 2006-04-05
US86266906P 2006-10-24 2006-10-24
US60/862,669 2006-10-24

Publications (1)

Publication Number Publication Date
KR20080103108A true KR20080103108A (ko) 2008-11-26

Family

ID=38521972

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087025237A Ceased KR20080103108A (ko) 2006-03-17 2007-03-16 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법
KR1020087025235A Withdrawn KR20080106976A (ko) 2006-03-17 2007-03-16 신경 줄기 세포 증식제 및 신경 줄기 세포 분화제의 연속 투여 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087025235A Withdrawn KR20080106976A (ko) 2006-03-17 2007-03-16 신경 줄기 세포 증식제 및 신경 줄기 세포 분화제의 연속 투여 방법

Country Status (8)

Country Link
US (3) US8143220B2 (https=)
EP (2) EP2004212A4 (https=)
JP (4) JP2009530235A (https=)
KR (2) KR20080103108A (https=)
AU (2) AU2007229301B2 (https=)
CA (2) CA2644116A1 (https=)
IL (2) IL193856A0 (https=)
WO (2) WO2007106987A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002325712C1 (en) * 2001-08-30 2008-07-31 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
WO2005077404A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US7534765B2 (en) 2005-09-27 2009-05-19 Stem Cell Therapeutics Corp. Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
KR20080103108A (ko) 2006-03-17 2008-11-26 스템 셀 테라퓨틱스 코포레이션 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법
US20090261690A1 (en) * 2006-09-25 2009-10-22 Tomoaki Mashimo Ultrasonic wave handling device and a microscopic in-tube inspection system
CA2698666A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US8198083B1 (en) 2007-10-31 2012-06-12 William Gunter Loudon Organotypic slices of the central nervous system
ES2628228T3 (es) * 2009-03-26 2017-08-02 Henry Ford Health System Timosina beta 4 para su utilización en el tratamiento de una lesión neural
US20120265129A1 (en) 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
WO2012156968A2 (en) * 2011-05-19 2012-11-22 Ariel - University Research And Development Company, Ltd. Use of mesenchymal stem cells for the improvement of affective and cognitive function
WO2013112002A1 (ko) * 2012-01-27 2013-08-01 의료법인 성광의료재단 뇌 손상 증세의 경감 또는 완화에 대한 바이오마커
MX2015004940A (es) 2012-10-18 2015-12-09 Neuralight Hd Llc Tratamiento de depresion y ptsd.
US11439668B2 (en) 2014-05-23 2022-09-13 JangoBio, LLC Methods to differentiate stem cells into hormone-producing cells
US11253549B2 (en) 2014-05-23 2022-02-22 JangoBio, LLC Methods to rebalance the hypothalamic-pituitary-gonadal axis
WO2017179225A1 (ja) * 2016-04-13 2017-10-19 味の素株式会社 加齢に伴う身体機能低下もしくは身体機能障害、または加齢に伴う精神機能低下もしくは精神機能障害の抑制または改善用組成物

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4902680A (en) 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
EP0397834B1 (en) 1988-10-28 2000-02-02 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
EP0441889A1 (fr) 1988-11-07 1991-08-21 Commission des Communautés Européennes Hormone de croissance humaine modifiee
US5128242A (en) * 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5198542A (en) * 1989-06-20 1993-03-30 Takeda Chemical Industries, Inc. Dna encoding a pitvitary adenylate cyclase activating protein and use thereof
US6329508B1 (en) * 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
EP0467279A3 (en) 1990-07-18 1992-08-05 Takeda Chemical Industries, Ltd. Polypeptides having c-amp producing activity
US5521069A (en) * 1990-08-10 1996-05-28 Takeda Chemical Industries, Ltd. Genomic DNA exons having exons encoding human pituitary adenylate cyclase activity peptide with 38 amino acids residues(PACAP38) and a promoter thereof
US5189179A (en) * 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5231178A (en) 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
US5723115A (en) 1991-05-02 1998-03-03 W. Alton Jones Cell Science Center, Inc. Inhibition of adipose tissue development and obesity
JP3417558B2 (ja) 1991-05-10 2003-06-16 ジェネンテク，インコーポレイテッド 配位子作用薬および拮抗薬の選択
US6429186B1 (en) 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
ES2198404T5 (es) 1991-07-08 2008-05-01 Neurospheres Holdings Ltd. Celulas progenitoras neurales que responden a factor de crecimiento y que se pueden hacer proliferar in vitro.
US6294346B1 (en) 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US5980885A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
AU2489992A (en) 1991-08-16 1993-03-16 Chiron Corporation Muteins of epidermal growth factor exhibiting enhanced binding at low ph
US5623050A (en) * 1991-08-22 1997-04-22 Takeda Chemical Industries, Ltd. Stable polypeptides having c-AMP production enhancing activity and the use thereof
US5253648A (en) * 1991-10-11 1993-10-19 Spacelabs Medical, Inc. Method and apparatus for excluding artifacts from automatic blood pressure measurements
JPH07508025A (ja) 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
AU683023B2 (en) 1992-10-16 1997-10-30 Neurospheres Holdings Ltd Remyelination using neural stem cells
EP0669973B9 (en) 1992-10-28 2007-10-10 NeuroSpheres Holdings Ltd. Biological factors and neural stem cells
US5877169A (en) * 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
CA2175992C (en) 1993-11-09 2008-04-01 Samuel Weiss In situ modification and manipulation of stem cells of the central nervous system
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US6399316B1 (en) 1994-02-25 2002-06-04 Takeda Chemical Industries, Ltd. PACAP receptor protein, method for preparing said protein, and use thereof
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US6239105B1 (en) * 1994-03-31 2001-05-29 Barbara A. Brewitt Homeopathic preparations of purified growth hormone
WO1995029690A1 (en) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
US5840576A (en) * 1994-07-20 1998-11-24 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5547143A (en) * 1994-08-24 1996-08-20 Alliedsignal Inc. Seat belt retractor with integrated load limiter
US6680295B1 (en) 1994-09-22 2004-01-20 The Administrators Of The Tulane Educational Fund Method and pharmaceutical composition for prevention and treatment of brain damage
JPH10505863A (ja) 1994-09-22 1998-06-09 ジ・アドミニストレーターズ・オブ・ザ・チューレン・エデュケイショナル・ファンド 脳障害の予防および治療のための方法および医薬組成物
FI971956L (fi) 1994-11-14 1997-07-04 Neurospheres Holdings Ltd Hermosolujen lisääntymisen säännöstely
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
AU6163196A (en) 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
US5547993A (en) * 1995-10-24 1996-08-20 Mitsubishi Chemical Corporation Therapeutic agent for glaucoma
WO1997016169A1 (en) * 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
US6346390B1 (en) 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US6017533A (en) * 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
AU3492497A (en) 1996-06-21 1998-01-07 Arris Pharmaceutical Corporation Bivalent molecules that form an activating complex with an erythropoietin receptor
IT1284876B1 (it) 1996-08-07 1998-05-22 Applied Research Systems Hcg come inibitore della collagenasi
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
CA2301693A1 (en) 1997-09-19 1999-04-01 Klaus Unsicker Cytokines having neurotrophic activity
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
CA2308135A1 (en) * 1997-10-31 1999-05-14 John G. Gleason Novel metal complexes
TW445295B (en) * 1997-12-31 2001-07-11 Shiu Li Wei Expression vector pcDNA3.1-HC for human erythropoietin, BHK-21 host cell line transformed therewith, and production of human erythropoietin using the transformed cell
US6812027B2 (en) * 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
US6242563B1 (en) * 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
SE9804064D0 (sv) * 1998-11-25 1998-11-25 A & Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
FR2794473B1 (fr) 1999-06-03 2003-09-26 Centre Nat Rech Scient Procede de multiplication de cellules souches
US6618698B1 (en) * 1999-08-12 2003-09-09 Quickturn Design Systems, Inc. Clustered processors in an emulation engine
US6395546B1 (en) 2000-02-01 2002-05-28 Neurogeneration, Inc. Generation of dopaminergic neurons from human nervous system stem cells
KR100358754B1 (ko) * 2000-02-14 2002-11-07 대한민국 인간의 조혈촉진제 생산을 위한 형질전환 돼지를 생산하는방법 및 그 형질전환 돼지
US7259146B2 (en) * 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
AU7107301A (en) 2000-07-18 2002-01-30 Nichimo Co. Ltd. Stem cell reinforcing material
IL156828A0 (en) 2001-01-12 2004-02-08 Waratah Pharmaceuticals Inc Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
US6740163B1 (en) 2001-06-15 2004-05-25 Seagate Technology Llc Photoresist recirculation and viscosity control for dip coating applications
US7132287B2 (en) 2001-06-18 2006-11-07 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5HT-1A agonists
CN100393110C (zh) 2001-07-19 2008-06-04 汤姆森许可公司 数字广播传输可靠接收的方法和系统
CA2364095C (en) 2001-07-20 2011-07-12 Neurostasis, Inc Production of radial glial cells
AU2002325712C1 (en) * 2001-08-30 2008-07-31 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
JP4906231B2 (ja) * 2001-09-14 2012-03-28 ステム セル セラピューティクス インコーポレイテッド プロラクチン誘導性の神経幹細胞数の増加ならびにその治療用途
WO2003024471A2 (en) 2001-09-18 2003-03-27 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
ITPR20010072A1 (it) 2001-10-26 2003-04-26 Firaco Srl Apparato e procedimento di sicurezza per veicoli di trasporto, in particolare aeromobili.
AU2003228050A1 (en) 2002-05-03 2003-11-17 Neuronova Ab Therapeutic use of PACAP, Maxadilan, PACAP receptor agonist and/or ADCYAP1R1 in the treatment of CNS disorders
WO2004011021A1 (en) 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
WO2004011497A1 (en) 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
DE60335743D1 (de) * 2002-11-20 2011-02-24 Neuronova Ab Verbindungen und verfahren zur erhöhung der neurogenese
NZ542092A (en) * 2003-03-27 2008-04-30 Janssen Pharmaceutica Nv Use of erythropoietin (EPO) in stroke recovery wherein the EPO is formulated for administration for a particular dosage regime
US20070111932A1 (en) 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
WO2005077404A1 (en) * 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
CA2582567A1 (en) 2004-10-07 2006-04-13 Stem Cell Therapeutics Corp. Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
US7534765B2 (en) 2005-09-27 2009-05-19 Stem Cell Therapeutics Corp. Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
KR20080103108A (ko) 2006-03-17 2008-11-26 스템 셀 테라퓨틱스 코포레이션 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법
WO2008077027A2 (en) 2006-12-18 2008-06-26 Case Western Reserve University Treatment of post-menopausal and post-hysterectomy mediated cognitive disorders
US20100028361A1 (en) * 2006-12-19 2010-02-04 Smith Mark A Brain-derived gonadotropins and cognition
US20080286234A1 (en) * 2007-05-15 2008-11-20 Eyink Daniel A Method for treating demyelinating diseases

Also Published As

Publication number Publication date
US8143220B2 (en) 2012-03-27
US8333974B2 (en) 2012-12-18
EP2004211A1 (en) 2008-12-24
US20080039389A1 (en) 2008-02-14
IL193857A0 (en) 2011-08-01
WO2007106987A1 (en) 2007-09-27
WO2007106986A1 (en) 2007-09-27
JP2009530235A (ja) 2009-08-27
EP2004211A4 (en) 2010-07-07
AU2007229301B2 (en) 2013-08-01
JP2009530234A (ja) 2009-08-27
AU2007229301A1 (en) 2007-09-27
EP2004212A4 (en) 2010-07-14
JP2010138202A (ja) 2010-06-24
AU2007229300B2 (en) 2013-08-01
EP2004212A1 (en) 2008-12-24
IL193856A0 (en) 2011-08-01
KR20080106976A (ko) 2008-12-09
CA2644116A1 (en) 2007-09-27
US20120270779A1 (en) 2012-10-25
US20090081205A1 (en) 2009-03-26
WO2007106986A8 (en) 2008-03-06
CA2643502A1 (en) 2007-09-27
AU2007229300A1 (en) 2007-09-27
JP2010138203A (ja) 2010-06-24

Similar Documents

Publication Publication Date Title
KR20080103108A (ko) 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법
US8343920B2 (en) Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
US20090274668A1 (en) Combined Regulation of Neural Cell Production
AU2002325712A1 (en) Differentiation of neural stem cells and therapeutic use theeof
JP4990634B2 (ja) 神経幹細胞の増殖および神経発生のための黄体化ホルモン（ＬＨ）、および絨毛性ゴナドトロピン（ｈＣＧ）の使用
CN101466396A (zh) 用于治疗神经障碍的lh或hcg和epo的给药方案
TW200808343A (en) Dosing regimens for neural stem cell proliferating agents and differentiating agents for the treatment of neurological disorders
US20060105958A1 (en) Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
HK1156232A (en) Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
AU2012201397A1 (en) Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081016

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120316

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130905

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20131129

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130905

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I